Recombinant adenovirus encoding H-ras ribozyme induces apoptosis in laryngeal cancer cells through caspase- and mitochondria-dependent pathways

Chih Hung Wang, Li Jen Tsai, Yeou Ping Tsao, Jer Tsong Hsieh, Wei Wen Chien, Ching Len Liao, Hsing Won Wang, Hsiao Sheng Liu, Show Li Chen

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Previously, we designed a ribozyme that targets the H-ras oncogene at the 12th codon mutation site (Chang et al., 1997). Ribozymes have antisense molecule and site-specific ribonuclease potential. In this study, an adenoviral vector was used to transduce the H-ras ribozyme into laryngeal cancer cells (HEp-2). This served to downregulate the H-ras gene expression in which this ribozyme performed antisense activity due to HEp-2 cells containing wild-type alleles in the 12th H-ras codon. Together, our data demonstrated that the recombinant adenovirus encoding H-ras ribozyme can be broadly regarded as a cytotoxic gene therapy in laryngeal cancer cells regardless of containing wild-type or mutant ras gene. In addition, the mechanism through which the H-ras ribozyme inhibited tumor growth was apoptosis and involved both caspase- and mitochondria-mediated pathways. The activators caspase-8 and -9 as well as the effector caspase-3 in the induction phase of apoptosis and the substrate PARP of caspase-3 in the execution phase were activated 48 h following the H-ras ribozyme treatment. Mitochondrial events characterized by the production of superoxide anion and the release of cytochrome c started at 24 h. Mitochondrial transmembrane potential loss occurred 48 h after the ribozyme treatment. However, Bcl-2 delayed cytochrome c release to the cytosol, but it could not protect the apoptosis effect, suggesting that cytochrome c release from mitochondria may not play a role in H-ras ribozyme-induced apoptosis.

Original languageEnglish
Pages (from-to)805-814
Number of pages10
JournalBiochemical and Biophysical Research Communications
Volume298
Issue number5
DOIs
Publication statusPublished - 2002
Externally publishedYes

Fingerprint

Catalytic RNA
Mitochondria
Laryngeal Neoplasms
Caspases
Adenoviridae
Cells
Apoptosis
ras Genes
Cytochromes c
Codon
Caspase 3
Effector Caspases
Gene therapy
Caspase 9
Caspase 8
Ribonucleases
Gene expression
Superoxides
Genetic Therapy
Membrane Potentials

Keywords

  • Apoptosis
  • Caspase
  • H-ras
  • Mitochondria

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics
  • Molecular Biology

Cite this

Recombinant adenovirus encoding H-ras ribozyme induces apoptosis in laryngeal cancer cells through caspase- and mitochondria-dependent pathways. / Wang, Chih Hung; Tsai, Li Jen; Tsao, Yeou Ping; Hsieh, Jer Tsong; Chien, Wei Wen; Liao, Ching Len; Wang, Hsing Won; Liu, Hsiao Sheng; Chen, Show Li.

In: Biochemical and Biophysical Research Communications, Vol. 298, No. 5, 2002, p. 805-814.

Research output: Contribution to journalArticle

Wang, Chih Hung ; Tsai, Li Jen ; Tsao, Yeou Ping ; Hsieh, Jer Tsong ; Chien, Wei Wen ; Liao, Ching Len ; Wang, Hsing Won ; Liu, Hsiao Sheng ; Chen, Show Li. / Recombinant adenovirus encoding H-ras ribozyme induces apoptosis in laryngeal cancer cells through caspase- and mitochondria-dependent pathways. In: Biochemical and Biophysical Research Communications. 2002 ; Vol. 298, No. 5. pp. 805-814.
@article{4f921d5f1ae34d149fc6c1bdabe7eb12,
title = "Recombinant adenovirus encoding H-ras ribozyme induces apoptosis in laryngeal cancer cells through caspase- and mitochondria-dependent pathways",
abstract = "Previously, we designed a ribozyme that targets the H-ras oncogene at the 12th codon mutation site (Chang et al., 1997). Ribozymes have antisense molecule and site-specific ribonuclease potential. In this study, an adenoviral vector was used to transduce the H-ras ribozyme into laryngeal cancer cells (HEp-2). This served to downregulate the H-ras gene expression in which this ribozyme performed antisense activity due to HEp-2 cells containing wild-type alleles in the 12th H-ras codon. Together, our data demonstrated that the recombinant adenovirus encoding H-ras ribozyme can be broadly regarded as a cytotoxic gene therapy in laryngeal cancer cells regardless of containing wild-type or mutant ras gene. In addition, the mechanism through which the H-ras ribozyme inhibited tumor growth was apoptosis and involved both caspase- and mitochondria-mediated pathways. The activators caspase-8 and -9 as well as the effector caspase-3 in the induction phase of apoptosis and the substrate PARP of caspase-3 in the execution phase were activated 48 h following the H-ras ribozyme treatment. Mitochondrial events characterized by the production of superoxide anion and the release of cytochrome c started at 24 h. Mitochondrial transmembrane potential loss occurred 48 h after the ribozyme treatment. However, Bcl-2 delayed cytochrome c release to the cytosol, but it could not protect the apoptosis effect, suggesting that cytochrome c release from mitochondria may not play a role in H-ras ribozyme-induced apoptosis.",
keywords = "Apoptosis, Caspase, H-ras, Mitochondria",
author = "Wang, {Chih Hung} and Tsai, {Li Jen} and Tsao, {Yeou Ping} and Hsieh, {Jer Tsong} and Chien, {Wei Wen} and Liao, {Ching Len} and Wang, {Hsing Won} and Liu, {Hsiao Sheng} and Chen, {Show Li}",
year = "2002",
doi = "10.1016/S0006-291X(02)02574-3",
language = "English",
volume = "298",
pages = "805--814",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Elsevier B.V.",
number = "5",

}

TY - JOUR

T1 - Recombinant adenovirus encoding H-ras ribozyme induces apoptosis in laryngeal cancer cells through caspase- and mitochondria-dependent pathways

AU - Wang, Chih Hung

AU - Tsai, Li Jen

AU - Tsao, Yeou Ping

AU - Hsieh, Jer Tsong

AU - Chien, Wei Wen

AU - Liao, Ching Len

AU - Wang, Hsing Won

AU - Liu, Hsiao Sheng

AU - Chen, Show Li

PY - 2002

Y1 - 2002

N2 - Previously, we designed a ribozyme that targets the H-ras oncogene at the 12th codon mutation site (Chang et al., 1997). Ribozymes have antisense molecule and site-specific ribonuclease potential. In this study, an adenoviral vector was used to transduce the H-ras ribozyme into laryngeal cancer cells (HEp-2). This served to downregulate the H-ras gene expression in which this ribozyme performed antisense activity due to HEp-2 cells containing wild-type alleles in the 12th H-ras codon. Together, our data demonstrated that the recombinant adenovirus encoding H-ras ribozyme can be broadly regarded as a cytotoxic gene therapy in laryngeal cancer cells regardless of containing wild-type or mutant ras gene. In addition, the mechanism through which the H-ras ribozyme inhibited tumor growth was apoptosis and involved both caspase- and mitochondria-mediated pathways. The activators caspase-8 and -9 as well as the effector caspase-3 in the induction phase of apoptosis and the substrate PARP of caspase-3 in the execution phase were activated 48 h following the H-ras ribozyme treatment. Mitochondrial events characterized by the production of superoxide anion and the release of cytochrome c started at 24 h. Mitochondrial transmembrane potential loss occurred 48 h after the ribozyme treatment. However, Bcl-2 delayed cytochrome c release to the cytosol, but it could not protect the apoptosis effect, suggesting that cytochrome c release from mitochondria may not play a role in H-ras ribozyme-induced apoptosis.

AB - Previously, we designed a ribozyme that targets the H-ras oncogene at the 12th codon mutation site (Chang et al., 1997). Ribozymes have antisense molecule and site-specific ribonuclease potential. In this study, an adenoviral vector was used to transduce the H-ras ribozyme into laryngeal cancer cells (HEp-2). This served to downregulate the H-ras gene expression in which this ribozyme performed antisense activity due to HEp-2 cells containing wild-type alleles in the 12th H-ras codon. Together, our data demonstrated that the recombinant adenovirus encoding H-ras ribozyme can be broadly regarded as a cytotoxic gene therapy in laryngeal cancer cells regardless of containing wild-type or mutant ras gene. In addition, the mechanism through which the H-ras ribozyme inhibited tumor growth was apoptosis and involved both caspase- and mitochondria-mediated pathways. The activators caspase-8 and -9 as well as the effector caspase-3 in the induction phase of apoptosis and the substrate PARP of caspase-3 in the execution phase were activated 48 h following the H-ras ribozyme treatment. Mitochondrial events characterized by the production of superoxide anion and the release of cytochrome c started at 24 h. Mitochondrial transmembrane potential loss occurred 48 h after the ribozyme treatment. However, Bcl-2 delayed cytochrome c release to the cytosol, but it could not protect the apoptosis effect, suggesting that cytochrome c release from mitochondria may not play a role in H-ras ribozyme-induced apoptosis.

KW - Apoptosis

KW - Caspase

KW - H-ras

KW - Mitochondria

UR - http://www.scopus.com/inward/record.url?scp=0036432830&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036432830&partnerID=8YFLogxK

U2 - 10.1016/S0006-291X(02)02574-3

DO - 10.1016/S0006-291X(02)02574-3

M3 - Article

C2 - 12419327

AN - SCOPUS:0036432830

VL - 298

SP - 805

EP - 814

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 5

ER -